Results 61 to 70 of about 15,257 (261)

Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea [PDF]

open access: green, 2023
Selam Mihreteab   +15 more
openalex   +1 more source

Process development priorities for scaling up direct microbial conversion of sugars into value‐added biochemicals

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The study identified process development priorities toward the feasible production of five value‐added biochemicals in a sugarcane biorefinery based on achievable bioconversion performances. Multiple process scenarios using A‐molasses as feedstock were simulated in Aspen Plus® via direct microbial conversions.
Manasseh K. Sikazwe   +2 more
wiley   +1 more source

Expression in Yeast Links Field Polymorphisms in PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor Classes [PDF]

open access: yes, 2017
Background. The mechanism of action of artemisinins against malaria is unclear, despite their widespread use in combination therapies and the emergence of resistance. Results.
Avery, Mitchell A.   +10 more
core  

Addressing the challenge of neonatal mortality.

open access: yes, 2013
Reducing neonatal mortality remains a challenge with an estimated 3.0 million neonatal deaths in 2011, three-quarters of these in sub-Saharan Africa and Southern Asia.
Blencowe, H, Cousens, S
core   +1 more source

Do Health Workers' Preferences Influence their Practices? Assessment of Providers' Attitude and Personal use of new Treatment Recommendations for Management of Uncomplicated Malaria, Tanzania. [PDF]

open access: yes, 2012
\ud \ud Due to growing antimalarial drug resistance, Tanzania changed malaria treatment policies twice within a decade. First in 2001 chloroquine (CQ) was replaced by sulfadoxine-pyrimethamine (SP) for management of uncomplicated malaria and by late 2006,
Khatib, Rashid A   +2 more
core   +3 more sources

Biological Actions of Artemisinin: Insights from Medicinal Chemistry Studies

open access: yesMolecules, 2010
Artemisinins have become essential antimalarial drugs for increasingly widespread drug-resistant malaria strains. Although tremendous efforts have been devoted to decipher how this class of molecules works, their exact antimalarial mechanism is still an ...
Jian Li, Bing Zhou
doaj   +1 more source

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Junjie Ding   +24 more
wiley   +1 more source

Artemisinin resistance--modelling the potential human and economic costs. [PDF]

open access: yes, 2014
BACKGROUND: Artemisinin combination therapy is recommended as first-line treatment for falciparum malaria across the endemic world and is increasingly relied upon for treating vivax malaria where chloroquine is failing.
Ashley, Elizabeth   +8 more
core   +1 more source

Artemisinin, the Magic Drug Discovered from Traditional Chinese Medicine

open access: yesEngineering, 2019
Artemisinin and its derivatives represent the most important and influential class of drugs in the fight against malaria. Since the discovery of artemisinin in the early 1970s, the global community has made great strides in characterizing and ...
Jigang Wang   +6 more
doaj   +1 more source

A whole‐genome scan for Artemisinin cytotoxicity reveals a novel therapy for human brain tumors

open access: yesEMBO Molecular Medicine, 2023
The natural compound Artemisinin is the most widely used antimalarial drug worldwide. Based on its cytotoxicity, it is also used for anticancer therapy.
Jasmin Taubenschmid‐Stowers   +21 more
doaj   +1 more source

Home - About - Disclaimer - Privacy